For the Inventor, By the Inventor

Enter assignee name

San Diego, CA, United States of America

Aragon Pharmaceuticals, Inc.

USPTO Granted Patents = 34

CIPO Patents = 5

EPO Patents = 17

Forward Citations = 152

Loading Chart...

Loading Chart...

30 inventors (with patents filed for the assignee):

Nicholas D Smith (15 out of 58 patents)

Mark R Herbert (9 out of 13 patents)

Ouathek Ouerfelli (8 out of 25 patents)

4. Isan Chen (8 out of 10 patents)

5. Anna Dilhas (6 out of 10 patents)

6. Celine Bonnefous (5 out of 12 patents)

7. Jackaline Dalgard Julien (5 out of 12 patents)

8. Arturo Molina (3 out of 3 patents)

9. Cyril Ben Haim (3 out of 6 patents)

10. Andras Horvath (3 out of 17 patents)

11. Johan Erwin Edmond Weerts (3 out of 9 patents)

12. Jennifer Albaneze-Walker (3 out of 3 patents)

13. Steven P Govek (2 out of 34 patents)

14. Geert Verreck (2 out of 2 patents)

15. Anna Dihas (2 out of 2 patents)

34 patents: Sort by Forward Citations

1. RE50642 - Anti-androgens for the treatment of non-metastatic castrate-resistant prostate cancer (2025-10-21),

2. 12303497 - Anti-androgens for the treatment of metastatic castration-sensitive prostate cancer (2025-05-20),

3. 12303493 - Anticancer compositions (2025-05-20),

4. 12018008 - Crystalline forms of an androgen receptor modulator (2024-06-25),

5. 11963952 - Anti-androgens for the treatment of metastatic castration-sensitive prostate cancer (2024-04-23),

6. 11911511 - Anticancer compositions (2024-02-27),

7. 11723898 - Androgen receptor inhibitors for the treatment of non-metastatic castration-resistant prostate cancer in subjects with severe hepatic impairment (2023-08-15),

8. RE49353 - Anti-androgens for the treatment of non-metastatic castrate-resistant prostate cancer (2023-01-02),

9. 11491149 - Anti-androgens for the treatment of non-metastatic castration-resistant prostate cancer (2022-11-08),

10. 11224575 - Anticancer compositions (2022-01-18),

11. 11160796 - Anti-androgens for the treatment of non-metastatic castration-resistant prostate cancer (2021-11-02),

12. 11040953 - Process for the preparation of a diarylthiohydantoin compound (2021-06-22),

13. 10934271 - Crystalline forms of an androgen receptor modulator (2021-03-02),

14. 10849888 - Anti-androgens for the treatment of non-metastatic castrate-resistant prostate cancer (2020-12-01),

15. 10799489 - Anti-androgens for the treatment of non-metastatic castrate-resistant prostate cancer (2020-10-13),

Aragon Pharmaceuticals, Inc. is a leading biotechnology company focused on developing innovative therapies for the treatment of various diseases. With a strong emphasis on research and development, we strive to bring breakthrough medications to patients in need. Our team of dedicated scientists and professionals work tirelessly to discover novel drug candidates and advance them through clinical trials. As a result, Aragon Pharmaceuticals is at the forefront of the industry, pioneering new approaches to disease management and pushing the boundaries of medical innovation.

This text is generated by artificial intelligence and may not be accurate.

Company Badge

USPTO Data Jan 1 1976 - Dec 30 2025

34 Patents

#175 in San Diego, CA

#2,306 in California

#9,680 in US

#19,060 in the World

San Diego, CA, United States of America

Aragon Pharmaceuticals, Inc.

Forward Citations = 152

30 inventors:

Nicholas D Smith (15 out of 58 patents)

Mark R Herbert (9 out of 13 patents)

Ouathek Ouerfelli (8 out of 25 patents)

4. Isan Chen (8 out of 10 patents)

5. Anna Dilhas (6 out of 10 patents)

Please report any incorrect information to support@idiyas.com

Loading…